Fernando Escalante - Concepedia

Author

Fernando Escalante

Instituto de Investigación Biomédica de Salamanca ORCID

Also Known As

Angel Ramirez-Payer, Aránzazu García, Escalante-Barrigón Escalante-Barrigón, F Escalante, F. Escalante, Felipe Martínez Escalante, Fernando Escalante, Fernando Escalante Barrigón, Fernando Escalante-Barrigon, Fernando Escalante-Barrigón

144

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Instituto de Investigación Biomédica de Salamanca Hospital de León Centro de Investigación del Cáncer Centro de Investigación Biomédica en Red de Cáncer Hospital General De Segovia

About

Fernando Escalante is an author at Instituto de Investigación Biomédica de Salamanca specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	467
2	Engineering	1	1	13
3	Health Sciences	1	1	46
4	Biomedical Engineering	1	1	13
5	Biostatistics	1	1	13

Fernando Escalante

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia Cristina Jiménez, Elena Sebastián, Carmen Chillón, Leukemia Myd88 L265pDisease MechanismGenetic DisorderPathogenesisPathology	2013	264
Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification Bruno Paiva, Maria-Carmen Montes, Ramón García‐Sánz, Leukemia Cell PathologyMedicineHematologyImmunologyHistopathology	2013	99
The cellular origin and malignant transformation of Waldenström macroglobulinemia Bruno Paiva, Luís A. Corchete, María‐Belén Vídriales, Blood	2015	97
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma Bruno Paiva, Mauricio Chandía, María‐Belén Vídriales, Blood	2014	93
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos, Clinical Lymphoma Myeloma & Leukemia	2018	89
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality Joaquín Martínez‐López, María‐Victoria Mateos, Cristina Encinas, Blood Cancer Journal	2020	75
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma Borja Puertas, Verónica González‐Calle, Eduardo Sobejano-Fuertes, Cancers	2023	67
Safety and efficacy of splenectomy in over 65‐yrs‐old patients with immune thrombocytopenia José Ramón González‐Porras, Fernando Escalante, Emilia Pardal, European Journal Of Haematology	2013	62
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero, Blood	2019	62
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival Ramón García‐Sánz, Irene Dogliotti, Gian Maria Zaccaria, British Journal of Haematology ImmunohematologyImmunodeficienciesImmunologyPathologyCell Death	2020	46

Page 1